retatrutide
Lilly’s triple agonist retatrutide posts strongest weight-loss data to date, with unusual sensory skin side effect reported
Eli Lilly; retatrutide; triple agonist; triple hormone receptor agonist; GLP-1; GIP; glucagon; obesity; weight loss; TRIUMPH-4; Phase III; dysesthesia; abnormal sense of touch; safety signal; side effects